You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Algorithm for Identifying Chemotherapy/Biological Regimens for Metastatic Colon Cancer in SEER-Medicare

Bikov, Kaloyan A. BS*; Mullins, C. Daniel PhD*; Seal, Brian PhD, RPh, MBA; Onukwugha, Eberechukwu PhD*; Hanna, Nader MD, FACS, FICS

Medical Care:
doi: 10.1097/MLR.0b013e31828fad9f
Applied Methods
Abstract

Background: Metastatic colon cancer (mCC) patients often receive multiple lines of chemotherapy/biological treatment (TX), yet subsequent TX lines have not been sufficiently examined using SEER-Medicare data. We developed an algorithm that identifies the number and type of TX lines received by mCC patients.

Methods: The algorithm rules for detecting TX lines were developed a priori and applied to SEER-Medicare data for 7951 elderly mCC patients, diagnosed in 2003–2007 and followed through 2009. Statistical analysis estimated the relationship between the number of treatments received and patient characteristics. Sensitivity analyses examined how results changed when different algorithm rules were used.

Results: Only 41% (3266) of mCC patients received any chemotherapy/biologics treatment; 1440 (18% of all, 44% of treated) and 274 (3% of all, 8% of treated) received second-line and third-line treatment, respectively. Initial and subsequent treatment regimens varied widely. Results were robust to alterations in the algorithm.

Conclusions: The number of drugs used to treat cancer patients has increased during the past decade. Patients may have several TX lines with complex regimens. More guidance is needed with regard to identifying and studying these interventions using SEER-Medicare data. By proposing 1 approach to categorizing TX lines for mCC patients, we hope to empower the scientific community and to advance the use of SEER-Medicare data for health outcomes research.

Author Information

*Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD

Bayer Healthcare Pharmaceuticals Inc., Wayne, NJ

Department of Surgery, Division of General and Oncologic Surgery, University of Maryland School of Medicine, Baltimore, MD

Supplemental Digital Content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website, www.lww-medicalcare.com.

Supported by Bayer Healthcare Pharmaceuticals, Inc.

C.D.M. currently has grants from Bayer and Pfizer; and consulting income from Amgen, Bayer, BMS, Celgene, GSK, Janssen/J&J, Mitsubishi, Novartis and Pfizer. E.O. has received grant support from Bayer, Novartis, Pfizer, and Sanofi Aventis; and consulting income from Janssen/J&J and Pfizer. B.S. is employed by Bayer and owns Bayer stocks. The other authors declare no conflict of interest.

Reprints: Kaloyan A. Bikov, BS, Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Saratoga Building, 12th Floor-PHSR, 220 Arch Street, Baltimore, MD 21201. E-mail: kbikov@rx.umaryland.edu.

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.